Providence Therapeutics
Focus: Providence Therapeutics is an mRNA cancer vaccine biotech founded in 2015 and headquartered in Calgary, Alberta, operating across oncology, infectious diseases, gene therapy, and vaccines. The company is publicly traded with a diversified pipeline spanning early-stage immunotherapies and cell therapies.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Providence Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Providence Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Providence Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A Multi-Center Trial of the ProLung Test™
Solitary Pulmonary NodulePamidronate
Transplant Bone DiseaseClinical Trials (1)
Help build intelligence for Providence Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.